Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke

Stroke. 2013 Nov;44(11):3217-9. doi: 10.1161/STROKEAHA.113.002859. Epub 2013 Sep 3.

Abstract

Background and purpose: Patients with renal impairment (RI) have an increased risk of both thrombotic and hemorrhagic events. We aimed to clarify whether RI increases the risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis with recombinant tissue plasminogen activator.

Methods: Patients who received intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset were retrospectively analyzed. Creatinine levels on admission served to calculate glomerular filtration rate (GFR) to estimate RI according to International Classification of Diseases criteria. Effect of RI on symptomatic ICH (sICH) was assessed using dichotomized (GFR <90 and <30 mL/min) and continuous GFR (centered data to test for linear and centered and squared data to test for curvilinear association).

Results: Of the 740 patients included, 83% had any RI (GFR <90 mL/min) and 5% had severe RI (GFR <30 mL/mL); 4.6% experienced sICH. Univariate comparisons revealed higher prevalence of sICH in patients with severe RI (P<0.01) but not with any RI. GFR as a continuous variable (centered and squared) was also associated with sICH (P=0.02), but GFR on its own was not. Severe RI and GFR (centered and squared) remained independently associated with sICH in multiple regression analyses.

Conclusions: Severe RI (GFR <30 mL/min) is associated with sICH after intravenous thrombolysis with recombinant tissue plasminogen activator. The association is curvilinear. Severe RI must be taken into account when balancing the risk-benefit ratio of intravenous thrombolysis with recombinant tissue plasminogen activator.

Keywords: acute renal failure; cerebral hemorrhage; stroke; thrombolytic therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / complications*
  • Aged
  • Aged, 80 and over
  • Brain Ischemia / complications
  • Brain Ischemia / therapy*
  • Cerebral Hemorrhage / etiology*
  • Female
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Male
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Regression Analysis
  • Retrospective Studies
  • Risk
  • Stroke / complications
  • Stroke / therapy*
  • Thrombolytic Therapy / adverse effects*
  • Thrombolytic Therapy / methods
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator